| Methods |
2‐ to 4‐week washout; 2‐week single‐blind placebo run‐in; inclusion criteria= mean sitting DBP 95‐114 mm Hg and did not vary by more than 10 mm Hg from the interday mean sitting DBP; 4‐week double‐blind treatment |
| Participants |
Tasosartan 10 mg: n=57(40 males,17 females); mean age=54 years: baseline sitting SBP=152 mm Hg, DBP=101 mm Hg;
Tasosartan 30 mg: n=55(43 males,12 females); mean age=52 years; baseline sitting SBP=151 mm Hg, DBP=101 mm Hg;
Tasosartan 100 mg: n=55(36 males,19 females); mean age=53 years; baseline sitting SBP=152 mm Hg, DBP=101 mm Hg;
Tasosartan 300 mg: n=55(35 males,20 females); mean age=53 years; baseline sitting SBP=152 mm Hg, DBP=101 mm Hg;
Placebo: n=56(33 males,23 females); mean age=55 years; baseline sitting SBP=152 mm Hg, DBP=100 mm Hg |
| Interventions |
Tasosartan 10 mg once daily;
Tasosartan 30 mg once daily;
Tasosartan 100 mg once daily;
Tasosartan 300 mg once daily;
Placebo;
taken between 7:30 and 9:30AM |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and 95% CI of change reported for tasosartan groups, BP change reported for placebo group, 95% CI of BP change not reported for placebo group, endpoint BP and SD not reported; calculated SD of change from 95% CI of change for tasosartan groups; imputed overall trial mean SBP/DBP SD of change for placebo group; BP data from Figure 1, p. 457; 95% CI data from text, p. 457; Jadad score=3; funding source= Wyeth Ayerst Research |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
